AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03668678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iGrow Readers Curriculum
Description: As part of the iGrow Readers curriculum, the primary teacher first reads a book as a group with a specific health behavior theme. Then, children participate in nutrition and physical activities that relate and reinforce the lessons learned in the book. Informational newsletters highlighting healthy behaviors from the stories' themes are provided to parents. All implementation strategies are reinforced by research to promote positive choices in young children's health behaviors through the use of literature and language strategies and modeling of others in the children's microsystems.
Study NCT00172029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT02263963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel
Description: In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.
Study NCT02263963 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TAP Block
Description: no intervention will be done to this arm.
Study NCT00648778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxapine Succinate Capsules 25 mg
Description: 25mg, single dose fasting
Study NCT00648778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxitane® Capsules 25 mg
Description: 25mg, single dose fasting
Study NCT00344448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
Study NCT00344448 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Raptiva
Description: During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
Study NCT02827955 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gamma Knife® radiosurgery bilateral
Study NCT03196063 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eccentric
Description: Exercises based on eccentric contractions of the quadriceps femoris muscle, using a 15º inclined plane. A serie of 15 repetitions of the squat will be performed, with the frequency of three times a week for eight weeks. The load of the exercises will be increased weekly.
Study NCT03196063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Protocol
Description: Protocol based on the Heavy Slow resistance program, with the addition of an isometric phase at the beginning of the protocol, and with exercises using body weight without the use of mechanotherapy.
Study NCT01126944 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: heart mate II
Description: left ventricular assist device
Study NCT04371939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II.
Study NCT04371939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I.
Study NCT04003740 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based transcranial direct current stimulation
Description: The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
Study NCT04003740 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Home-based transcranial direct current stimulation
Description: The stimulation protocol will include one daily stimulation during the first 4 weeks, 2 weekly stimulations for the next 4 weeks, and one weekly stimulation over the last 4 weeks.
Study NCT04431492 — intervention group
Intervention type: PROCEDURE
Intervention: CABG
Description: aminoacids and NO levels
Study NCT02435420 — intervention group
Intervention type: DEVICE
Intervention: EMPERION Modular Primary Stem
Description: Primary total hip arthroplasty using the EMPERION Modular Primary Stem
Study NCT00099658 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide-protein conjugate vaccine
Description: Injection administered three times before the age of 24 weeks
Study NCT02998658 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal cuff closure using conventional sutures
Description: Vaginal cuff will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
Study NCT06226116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: socket preservation
Description: After the tooth extraction the investigator will select two sockets, one will be assigned as the experimental side and we will preserve it with cold-processed autologous dentin. The second will be designated the control group and we will only stabilize the blood clot.
Study NCT06226116 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placement of experimental implants
Description: After four months of preservation, titanium cylinders measuring 2 mm wide by 8 mm long, with a Bioetch® surface, will be placed.
Study NCT02268825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: MK-3475 in combination with mFOLFOX6 in a 14 day cycle~Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV~MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)~Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks~Safety Expansion: MK-3475 at highest tolerated dose
Study NCT03979885 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation counseling (Quitline)
Description: Quitline offers community-based counseling session with a cessation counselor.
Study NCT06226116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: placement of experimental implants
Description: After four months of preservation, titanium cylinders measuring 2 mm wide by 8 mm long, with a Bioetch® surface, will be placed.
Study NCT06226116 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: histological sample collection
Description: Biopsy with trephine of a bone portion of 4mm in diameter and 10mm in length, which includes the titanium cylinder inside.~Placement of conventional implant 5mm wide by 10mm long.
Study NCT06226116 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: histological sample collection
Description: Biopsy with trephine of a bone portion of 4mm in diameter and 10mm in length, which includes the titanium cylinder inside.~Placement of conventional implant 5mm wide by 10mm long.
Study NCT03852485 — intervention group
Intervention type: DEVICE
Intervention: SD-OCT
Description: Spectral Domain Optical Coherence Tomography for non-invasive, light-based, cross-sectional imaging of ocular structures
Study NCT01617889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental powdered milk-based infant formula with an alternate fat blend
Description: formula to be consumed ad lib
Study NCT01617889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A powdered milk-based infant formula, standard fat blend
Description: formula to be consumed ad lib
Study NCT00955097 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity®
Description: Definity® injections given both pre-ablation and post-ablation
Study NCT00689195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin powder
Description: oral capsules containing the investigational agent
Study NCT00689195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ashwagandha extract
Description: 4.5% extract of ashwagandha
Study NCT01362309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: d-cycloserine.
Description: 50 mg administered on two occasions.
Study NCT03547960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Guar gum
Description: Fibre supplement to be taken with each meal
Study NCT03547960 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cellulose
Description: Placebo. Fibre supplement to be taken with each meal
Study NCT01376115 — intervention group
Intervention type: DRUG
Intervention: Nelarabine
Study NCT04362527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone 1 Mg/mL Solution for Injection
Description: Blinding procedure will be set up for the administration of the treatment
Study NCT04362527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution for injection
Description: Blinding procedure will be set up for the administration of the treatment
Study NCT00937703 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: paper support for glycaemia face to face visit at T4mounths
Study NCT00937703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IVS
Description: patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.~Face to face visit at T4mounths plus telephone visits each 2 weeks.
Study NCT00937703 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PDAphone
Description: Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
Study NCT04362514 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MEPC - Multi-component exercise program related to cycling
Description: Structured and progressive multicomponent exercise program with and without bikes. Training period will last over 3 months with 8 sessions à 60 minutes. Training sessions will address motor competence (balance, strength, cycling skills and techniques) and cognitive skills required during cycling. Furthermore, fall-related psychological concerns will be addressed.
Study NCT04362514 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HRP - health-related presentations
Description: HRP include 3 presentations on healthy aging (one per month) with a duration of 60 minutes
Study NCT01102439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 300 mg loading dose, then 75 mg daily
Study NCT01102439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
Study NCT01102439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: 81 mg daily
Study NCT01362309 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-cycloserine.
Description: 50 mg administered on two occasions.
Study NCT03979885 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)
Description: Participants will be encouraged to speak to their doctors about using highly effective pharmacotherapies for smoking cessation.
Study NCT01102439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 325 mg daily
Study NCT02489994 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ePrime
Description: The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
Study NCT03278964 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Orbital decompression
Study NCT03278964 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orbital decompression
Study NCT00733863 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00733863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAD106
Study NCT03237767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MIE
Description: The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold.
Study NCT02467504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hrIL-2 active
Description: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
Study NCT03237767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIE
Description: The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.~The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery.
Study NCT03591237 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: The patients participate in eight weekly group sessions of two hours each and will be asked to do an additional 45 minutes of daily training at home. The participants will be asked to record their home training to allow assessment of their adherence to the intervention. Generally, the program corresponds to the manualized MBCT program, but with adaptations that take into account the special needs of cancer patients, including shorter sessions, shorter yoga exercises and the omission of the all-day session. The sessions include psychoeducation and formalized mindfulness exercises with focus on the participants' here-and-now experience of their pain.
Study NCT01464658 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: panniculectomy
Description: surgery
Study NCT03552575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Description: Sacubitril is a prodrug neprilysin inhibitor used in combination with valsartan to reduce the risk of cardiovascular events in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
Study NCT03552575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: is an angiotensin II receptor antagonist (commonly called an ARB, or angiotensin receptor blocker), that is selective for the type I (AT1) angiotensin receptor.
Study NCT01052545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit-Feedback
Description: Applied as a post-prescription antimicrobial review based on established guidelines.
Study NCT05081856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mobilization with moduler medical equipment carring vehicle
Description: Mobilization of the patients was carried out with the vehicle in their modular vehicle.
Study NCT03979885 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Financial incentives for smoking cessation
Description: Participants will receive financial incentives for bioconfirmed smoking cessation.
Study NCT03979885 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Financial incentives for use of evidence-based smoking cessation therapies
Description: Participants will receive financial incentives for the use of evidence-based smoking cessation therapies including Quitline counseling, community-based smoking cessation programs and pharmacotherapies
Study NCT02870101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nucleic acid amplification test 1 for NG and CT
Description: A combination test using real-time PCR to detect DNA from NG and CT.
Study NCT02870101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nucleic acid amplification test 2 for NG and CT
Description: A combination test using target amplification to detect RNA from NG and CT.
Study NCT02870101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nucleic acid amplification test 3 for NG and CT
Description: A combination test using real-time PCR to detect DNA from NG and CT.
Study NCT02768519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTS167IV
Description: diluted to final concentration with cherry syrup
Study NCT02768519 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cherry syrup
Study NCT01795313 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLA-A2 restricted synthetic tumor antigen
Study NCT01237236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEE011
Study NCT01393639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 1 mg tablet once daily (QD) for 8 weeks
Study NCT01393639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 5 mg tablet once daily (QD) for 8 weeks
Study NCT01795313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Study NCT01795313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enzyme-linked immunosorbent assay
Study NCT01393639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 10 mg tablet once daily (QD) for 8 weeks
Study NCT01393639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04171327
Description: 15 mg tablet once daily (QD) for 8 weeks
Study NCT01393639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 5 mg capsule once daily for 8 weeks
Study NCT01795313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Study NCT01795313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT01795313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT04015050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: milk based infant formula
Description: Cows milk ased infant formula
Study NCT04015050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk based infant formula
Description: Cows milk ased infant formula
Study NCT02467504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: hrIL-2 placebo
Description: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
Study NCT02467504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Methotrexate (oral administration)
Study NCT02467504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MTX
Description: Methotrexate (oral administration)
Study NCT02467504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folic Acid
Description: Folic Acid (oral administration)
Study NCT02467504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folic Acid
Description: Folic Acid (oral administration)
Study NCT02467504 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loxoprofen
Description: Loxoprofen (oral administration)
Study NCT02467504 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loxoprofen
Description: Loxoprofen (oral administration)
Study NCT01393639 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: 10 mg capsule once daily for 8 weeks
Study NCT01393639 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (tablet or capsule) once daily (QD) for 8 weeks
Study NCT01966224 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection
Description: Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.~Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose.